Global Protein Therapeutics Market 2017-2021


◆タイトル:Global Protein Therapeutics Market 2017-2021
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:PDF / 英語
Single User(1名利用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,500 ⇒換算¥508,500見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。



About Protein TherapeuticsTherapeutic proteins are used to effectively treat a wide array of diseases such as protein deficiency diseases; chronic diseases such as cancer, rheumatoid arthritis (RA), ankylosing spondylitis, diabetes; infections such as human immunodeficiency virus (HIV), hepatitis A, hepatitis B, and hepatitis C; and other medical conditions such as genetic disorders, anemia cases related to kidney dialysis, and cancer-related anemia. Therapeutic proteins mostly consist of recombinant forms of naturally occurring proteins.

Technavio’s analysts forecast the global protein therapeutics market to grow at a CAGR of 7.86% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global protein therapeutics market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded and biosimilar drugs used for the treatment of various diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
• Americas

Technavio’s report, Global Protein Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AbbVie
• Amgen
• F. Hoffmann-La Roche
• Johnson & Johnson
• Merck
• Novo Nordisk

[Other prominent vendors]
• Anhui Anke Biotechnology (Group)
• AstraZeneca
• Baxter International
• Biocon
• Biodel
• BioGenomics
• Biopartners
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Celltrion
• Chugai Pharmaceutical
• Diamyd Medical
• Diasome Pharmaceuticals
• DiaVacs
• Dynavax Technologies
• Eli Lilly
• Ferring Pharmaceuticals
• Generex Biotechnology
• GeneScience Pharmaceuticals
• Hualan Biological Engineering
• Intas Pharmaceuticals
• Ipsen
• JCR Pharmaceuticals
• Kyowa Hakko Kirin
• Lexicon Pharmaceuticals
• LG Life Sciences
• MacroGenics
• MannKind
• Oramed Pharmaceuticals
• Osiris Therapeutics
• Pfizer
• Sandoz International
• Sanofi
• Teva Pharmaceutical Industries
• Thermalin Diabetes
• Tolerion
• Wockhardt

[Market driver]
• Increased demand for mAbs
• For a full, detailed list, view our report

[Market challenge]
• Complexities in manufacturing, storage conditions, distribution policies, and high cost
• For a full, detailed list, view our report

[Market trend]
• Emergence of next-generation biologics
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


Table of Contents
PART 01: Executive summary
• Alternate therapies hinder the growth possibilities of approved therapies

PART 02: Scope of the report
• Market overview
• Assumptions
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Highlights

PART 05: Market landscape
• Market overview
• Five forces analysis

PART 06: Market segmentation by product type
• Global mAbs market
• Global human insulin market
• Global clotting factors market
• Global EPO market
• Global human growth hormone market

PART 07: Market segmentation by therapy area
• Metabolic and endocrine disorders
• Hematopoiesis
• Fertility
• Cancer
• Autoimmune diseases
• Infectious diseases
• Protein vaccine

PART 08: Market segmentation by protein function
• Enzymatic and regulatory activity
• Special targeting activity
• Vaccines
• Protein diagnostics

PART 09: Geographical segmentation
• Protein therapeutics market in Americas
• Protein therapeutics market in EMEA
• Protein therapeutics market in APAC

PART 10: Market drivers
• Increased demand for mAbs
• Development of novel therapies using innovative technologies
• Availability of favorable reimbursement policies

PART 11: Impact of drivers

PART 12: Market challenges
• Complexities in manufacturing, storage conditions, distribution policies, and high cost
• Complicated regulatory framework
• Alternate therapies loom large

PART 13: Impact of drivers and challenges

PART 14: Market trends
• Emergence of next-generation biologics
• Advent of biosimilars expected to improve the treatment rates
• Strategic alliances further boost the R&D efforts

PART 15: Vendor landscape
• Competitive scenario
• Market share analysis 2016
• Other prominent vendors

PART 16: Key vendor analysis
• F. Hoffmann-La Roche
• Novo Nordisk
• Amgen
• AbbVie
• Johnson & Johnson
• Merck

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Overview of protein therapeutics market 2016-2021
Exhibit 03: Key strategies in global protein therapeutics market
Exhibit 04: Global protein therapeutics market snapshot: Developed and emerging markets 2015
Exhibit 05: Global protein therapeutics market 2016-2021 ($ billions)
Exhibit 06: Patent expirations of major biologics 2000-2030
Exhibit 07: Impact of factors affecting the market 2016 and 2021
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of global protein therapeutics market by product type
Exhibit 10: Market share of global protein therapeutics market by product type
Exhibit 11: Overview of global mAbs market
Exhibit 12: Annual treatment cost per patient for various drugs 2015
Exhibit 13: Global mAbs market: Present and future scenario
Exhibit 14: Global mAbs market 2016-2021 ($ billions)
Exhibit 15: Opportunity analysis of global mAbs market
Exhibit 16: Year-over-year (YoY) sales comparison of mAbs 2013-2015 ($ billions)
Exhibit 17: Market overview of human insulin
Exhibit 18: Global human insulin market 2016-2021 ($ billions)
Exhibit 19: Factors affecting global human insulin market
Exhibit 20: Opportunity analysis of global human insulin market
Exhibit 21: Revenues from the sales of top five products in insulin market 2013-2015 ($ billions)
Exhibit 22: Market overview of clotting factors
Exhibit 23: Global clotting factors market 2016-2021 ($ billions)
Exhibit 24: Opportunity analysis of global clotting factors market
Exhibit 25: Market overview of EPO
Exhibit 26: Global EPO market 2016-2021 ($ billions)
Exhibit 27: Globally approved EPO biosimilars
Exhibit 28: Opportunity analysis of global EPO market
Exhibit 29: Market overview of human growth hormone
Exhibit 30: Global human growth hormone market 2016-2021 ($ billions)
Exhibit 31: Opportunity analysis of global human growth hormone market
Exhibit 32: Segmentation of global protein therapeutics market by therapy area
Exhibit 33: Segmentation of global protein therapeutics market by protein function
Exhibit 34: Global protein therapeutics market: Segmentation by geography (2016-2021)
Exhibit 35: Global protein therapeutics market segmentation by region: Market growth lifecycle analysis 2016
Exhibit 36: Overview of protein therapeutics market in Americas
Exhibit 37: Protein therapeutics market in Americas 2016-2021 ($ billions)
Exhibit 38: Protein therapeutics market in Americas: Opportunity analysis
Exhibit 39: Overview of protein therapeutics market in EMEA
Exhibit 40: Protein therapeutics market in EMEA 2016-2021 ($ billions)
Exhibit 41: Protein therapeutics market in EMEA: Opportunity analysis
Exhibit 42: Overview of protein therapeutics market in APAC
Exhibit 43: Protein therapeutics market in APAC 2016-2021 ($ billions)
Exhibit 44: Protein therapeutics market in APAC: Opportunity analysis
Exhibit 45: mAb approvals by the US FDA and EMA 2010-2015
Exhibit 46: Advances in ADCs technology
Exhibit 47: Few of other technologies used in protein therapeutics
Exhibit 48: Impact of drivers
Exhibit 49: Approval process of biologicals versus biosimilars via Public Health Service Act (PHSA) in US
Exhibit 50: Few of CAM therapies used for autoimmune and inflammatory diseases
Exhibit 51: Impact of drivers and challenges
Exhibit 52: Overview of next-generation antibodies
Exhibit 53: Oral insulin pipeline portfolio
Exhibit 54: Few of the biosimilars under development
Exhibit 55: Key deals in global protein therapeutics market
Exhibit 56: Market presence of vendors in various therapy areas 2015
Exhibit 57: Competitive assessment of vendors
Exhibit 58: Geographical presence of key vendors
Exhibit 59: F. Hoffmann-La Roche: Profile
Exhibit 60: F. Hoffmann-La Roche: Strength assessment
Exhibit 61: F. Hoffmann-La Roche: Strategy assessment
Exhibit 62: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 63: Novo Nordisk: Profile
Exhibit 64: Novo Nordisk: Strength assessment
Exhibit 65: Novo Nordisk: Strategy assessment
Exhibit 66: Novo Nordisk: Opportunity assessment
Exhibit 67: Amgen: Profile
Exhibit 68: Amgen: Strength assessment
Exhibit 69: Amgen strategy assessment
Exhibit 70: Amgen: Opportunity assessment
Exhibit 71: AbbVie: Profile
Exhibit 72: AbbVie: Strength assessment
Exhibit 73: AbbVie: Strategy assessment
Exhibit 74: AbbVie: Opportunity assessment
Exhibit 75: Johnson & Johnson: Profile
Exhibit 76: Johnson & Johnson: Strength assessment
Exhibit 77: Johnson & Johnson: Strategy assessment
Exhibit 78: Johnson & Johnson: Opportunity assessment
Exhibit 79: Merck: Profile
Exhibit 80: Merck: Strength assessment
Exhibit 81: Merck: Strategy assessment
Exhibit 82: Merck: Opportunity assessment


AbbVie, Amgen, F. Hoffmann-La Roche, Johnson & Johnson, Merck, Novo Nordisk, Anhui Anke Biotechnology, AstraZeneca, Baxter International, Biocon, Biodel, BioGenomics, Biopartners, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Chugai Pharmaceutical, Diamyd Medical, Diasome Pharmaceuticals, DiaVacs, Dynavax Technologies, Eli Lilly, Ferring Pharmaceuticals, Generex Biotechnology, GeneScience Pharmaceuticals, Hualan Biological Engineering, Intas Pharmaceuticals, Ipsen, JCR Pharmaceuticals, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, LG Life Sciences, MacroGenics, MannKind, Oramed Pharmaceuticals, Osiris Therapeutics, Pfizer, Sandoz International, Sanofi, Teva Pharmaceutical Industries, Thermalin Diabetes, Tolerion, Wockhardt, XOMA.





★調査レポート[蛋白質治療の世界市場2017-2021:mAbs、ヒトインスリン、凝固因子、EPO、ヒト成長ホルモン] (Global Protein Therapeutics Market 2017-2021 / IRTNTR11316)販売に関する免責事項
[蛋白質治療の世界市場2017-2021:mAbs、ヒトインスリン、凝固因子、EPO、ヒト成長ホルモン] (Global Protein Therapeutics Market 2017-2021 / IRTNTR11316)についてEメールでお問い合わせ